Hostname: page-component-586b7cd67f-l7hp2 Total loading time: 0 Render date: 2024-11-30T10:39:42.895Z Has data issue: false hasContentIssue false
  • English
  • Français

EPA-1435 - Add-on Clinical Effects of Simvastatin and Ondansetron in Patients with Schizophrenia Stabilized on Antipsychotic Treatment: Pilot study

Published online by Cambridge University Press:  15 April 2020

I.B. Chaudhry ,
N. Husain ,
R.J. Drake ,
G. Dunn ,
M. Husain ,
A. Kazmi ,
M.M. Hamirani ,
R. Rahman ,
J. Stirling  and
J.F.W. Deakin
I.B. Chaudhry
Affiliation:
Psychiatry, University of Manchester, Manchester, United Kingdom
N. Husain
Affiliation:
Psychiatry, University of Manchester, Manchester, United Kingdom
R.J. Drake
Affiliation:
Psychiatry, University of Manchester, Manchester, United Kingdom
G. Dunn
Affiliation:
Psychiatry, University of Manchester, Manchester, United Kingdom
M. Husain
Affiliation:
Psychiatry, Greater Manchester West Mental Health Trust, Manchester, United Kingdom
A. Kazmi
Affiliation:
Research and Development, Pakistan Institute of Learning and Living, Karachi, Pakistan
M.M. Hamirani
Affiliation:
Psychiatry, Karachi Dental and Medical College, Karachi, Pakistan
R. Rahman
Affiliation:
Psychiatry, Dow University of Health Sciences, Karachi, Pakistan
J. Stirling
Affiliation:
Psychiatry, Manchester Metropolitan University, Manchester, United Kingdom
J.F.W. Deakin
Affiliation:
Psychiatry, University of Manchester, Manchester, United Kingdom

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Objectives

There is some evidence that anti-inflammatory treatment may have beneficial effects in schizophrenia and major depression. Statins are cholesterol-lowering agents but have been found to be anti-inflammatory and also decrease C-reactive protein (CRP). Ondansetron is a serotonin (5-HT3) receptor antagonist widely used to prevent nausea and vomiting in patients receiving chemotherapy for cancer. Small studies have suggested that adjunctive Ondansetron is efficacious against schizophrenia symptoms. We carried out a feasibility study in schizophrenia patients (within 5 years of first diagnosis) to explore the adjunctive use of simvastatin and ondansetron on positive, negative and general psychopathology.

Methods

This was a 12 week rater blind placebo controlled study. All to gather 36 patients with DSM-IV diagnosis of schizophrenia were recruited, 12 in each arm. Patients were assessed at baseline and at 12 weeks using PANSS, CGI, GAF and AIMS.

Results

Both simvastatin and ondansetron provide some evidence of a reduction in symptoms compared to treatment as usual (TAU) on PANSS total score, although, this was not statistically significant. In the secondary analyses, no significant differences were seen on CGI, GAF and AIMS.

Conclusions

Anti-inflammatory treatments have shown to have some beneficial effects in schizophrenia. Both simvastatin and ondansetron provide some evidence of a reduction in symptoms compared to treatment as usual. This study has led to a larger SMRI-funded, double blind, randomized control trial.

Type
E01 - e-Poster Oral Session 01: Schizophrenia
Information
European Psychiatry , Volume 29 , Issue S1: Abstracts of the 22nd European Congress of Psychiatry , 2014 , pp. 1
Copyright
Copyright © European Psychiatric Association 2014
Submit a response

Comments

No Comments have been published for this article.